A b s t r a c t

We assessed the distribution and expression of inducible nitric oxide synthase (i-NOS), endothelial nitric oxide synthase (e-NOS), and xanthine oxidase (XAO) in usual interstitial pneumonia, desquamative interstitial pneumonia, and granulomatous diseases. The material consisted of biopsy specimens from 5 healthy subjects (nonsmokers), 9 patients with usual interstitial pneumonia, 11 with desquamative interstitial pneumonia, 14 with sarcoidosis, and 8 with extrinsic allergic alveolitis. i-NOS was expressed intensively in inflammatory but not in fibrotic lesions. It was expressed most prominently in alveolar macrophages and alveolar epithelium of all disorders and in the granulomas of sarcoidosis and extrinsic allergic alveolitis. In contrast with i-NOS, e-NOS was expressed prominently in control lung tissue samples but also in granulomas of sarcoidosis and extrinsic allergic alveolitis. Reverse transcription-polymerase chain reaction performed on bronchoalveolar lavage fluid samples from patients with sarcoidosis or usual interstitial pneumonia and from healthy subjects indicated positivity for XAO, but immunohistochemical analysis in samples from healthy lung and all parenchymal lung disorders showed no immunoreactivity for XAO. i-NOS has an important role in the pathogenesis of interstitial lung diseases, being up-regulated during the inflammatory but not during the fibrotic disease stage.
A central role in the pathogenesis of different lung diseases has been suggested for free radicals and reactive oxygen species (ROS), but the importance of various ROS generating pathways in these disorders remains unclear. Free radicals also are associated with the synthesis of extracellular matrix proteins, both in animal models of bleomycin-induced fibrosis and in cell culture conditions, 1 and they may have a role in the fibrogenesis of human lung. Interstitial lung diseases of human lung have variable prognoses; poor prognosis usually is associated with progressive fibrogenesis. 2 These diseases include interstitial pneumonias, such as usual interstitial pneumonia (fibrosing alveolitis) and desquamative interstitial pneumonia, and granulomatous disorders, such as sarcoidosis and extrinsic allergic alveolitis. 2, 3 The typical feature in most of these diseases is activation of inflammatory cells, which has multiple consequences, one of which is various ROS-generating mechanisms in the cells. 4 Reactive oxygen metabolites can be generated by multiple pathways. It is well known that human inflammatory cells contain NADPH oxidase that is activated in the inflammatory conditions of the lung. Inflammatory cells, bronchial epithelial cells, and endothelial cells also are capable of producing nitric oxide (NO) mainly by inducible NO synthase (i-NOS) and by endothelial NO synthase (e-NOS). 4 i-NOS is expressed weakly in healthy human lung 5, 6 but is up-regulated by inflammatory cytokines 7, 8 through activation of nuclear factor-kappaB 9 in multiple cell types of the lung. [10] [11] [12] Its expression has been described in patients with asthma, 11 pulmonary hypertension, immunocomplexmediated injury, adult respiratory distress syndrome, 10 and unclassified pulmonary fibrosis. 12 Expression of i-NOS also has been detected during experimental granuloma formation in vitro and in granulomatous inflammation caused by silica, zymosan, and dextran beads in vivo. [13] [14] [15] [16] e-NOS, which is expressed constitutively mainly in the endothelium, is regulated by calcium and oxygen concentration, growth factors, and cytokines. 17 NO synthase may have an important role in the pathogenesis and progression of human interstitial lung diseases, since NO has direct toxic effects and also reacts with superoxide and generates toxic peroxynitrite in the cells.
In addition to NADPH oxidase, superoxide radicals are produced by intracellular xanthine oxidase (XAO). 18, 19 XAO exists mainly as a dehydrogenase form, but only the oxidase form of the enzyme is associated with the generation of superoxide and hydrogen peroxide. 20 XAO is expressed highly in human liver and intestine, but its expression and activity are low or not detectable in healthy human lung. [21] [22] [23] Its low activity, however, does not exclude its expression in a subpopulation of the cells, but so far no studies are available on XAO in human lung diseases.
To better understand the role of various oxidant-generating pathways in the pathogenesis and progression of interstitial lung diseases, we studied the expression of i-NOS, e-NOS, and XAO in healthy human lung in 2 forms of chronic interstitial pneumonia (usual and desquamative) and in parenchymal forms of granulomatous diseases: sarcoidosis and extrinsic allergic alveolitis.
Materials and Methods
Patients
Histopathologically typical cases of usual interstitial pneumonia (n = 9), desquamative interstitial pneumonia (n = 11), sarcoidosis (n = 14), and extrinsic allergic alveolitis (ie, farmer's lung; n = 8) were retrieved from the files of the Department of Pathology, Oulu University Hospital, Oulu, Finland. Diagnoses of all patients were based on light microscopic evaluations using the histologic criteria presented by Katzenstein and Myers. 2 Clinical information for the patients was obtained from the records at the University Hospital and the nearby former tuberculosis hospital (Päivärinne, Muhos, Finland). The patients with usual interstitial pneumonia were 43 to 66 years old, the female/male ratio was 7:2, and 2 of the patients were former or current smokers; the patients with desquamative interstitial pneumonia were 29 to 58 years old, the female/male ratio was 5:6, and 9 of the patients were smokers. The patients with sarcoidosis were 26 to 69 years old, the female/male ratio was 9:5, and 3 of the patients were smokers, whereas patients with extrinsic allergic alveolitis were 25 to 64 years old, the female/male ratio was 3:5, and 5 patients were former or current smokers.
Biopsies
Diagnostic lung biopsy was performed because of parenchymal involvement. The biopsy specimens were obtained from different parts of the left or right lung. The biopsy material was fixed in 10% formalin under vacuum to expand the tissue and to remove air bubbles or perfused by injecting the fixative, using a small syringe, into bronchioles as described by Dail and Hammar. 24 The specimens then were dehydrated and embedded in paraffin. Uninvolved peripheral lung tissue, used as a control, was obtained from 5 nonsmokers operated on for a malignant lung tumor or a carcinoid tumor. None of the control subjects received corticosteroid therapy before the biopsy, and their lung function parameters were normal.
The biopsy of human small intestine for the assessment of XAO immunoreactivity was obtained from a patient who underwent ileectomy because of ileum strangulation.
Bronchoalveolar Lavage Fluid Samples
To study the expression of these enzymes at the alveolar level, 2 bronchoalveolar lavage (BAL) samples from patients with usual interstitial pneumonia, sarcoidosis, or extrinsic allergic alveolitis and from 1 healthy control subject (examined for minor respiratory symptoms) were collected in a 4-mol/L concentration of thiocyanate buffer and frozen immediately at -80°C. The diagnoses of the patients with usual interstitial pneumonia, sarcoidosis, and extrinsic allergic alveolitis were later confirmed by biopsies.
Immunohistochemical Analysis
Sections 4 µm thick were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase was consumed by incubating the sections in 30% hydrogen peroxide in absolute methanol for 10 minutes. The monoclonal antibody for i-NOS was obtained from Transduction Laboratories (Lexington, KY), the polyclonal antibody for e-NOS from Santa Cruz Biotechnology (San Diego, CA), and the polyclonal antibody for XAO was a gift from professor Kari O. Raivio, MD, PhD (University of Helsinki, Helsinki, Finland). 25 The sections were incubated with the primary antibodies (anti-i-NOS, dilution 1:60; anti-e-NOS, dilution 1:50; and anti-XAO, dilution 1:100) at room temperature for 1 hour followed by the biotinylated secondary antibody and peroxidase conjugated streptavidin included in the Histostain-PLUS kit (Zymed Laboratories, South San Francisco, CA). The color was developed with aminoethyl carbazole substrate solution (Zymed Laboratories). The sections were counterstained with a light hematoxylin stain. The negative controls consisted of substituting phosphate-buffered saline, pH 7.2, and rat and rabbit isotypes recommended by the manufacturer for i-NOS and e-NOS and nonimmune rabbit serum for XAO. To further assess the localization of i-NOS and e-NOS in fibroblastic foci, serial sections were stained with an antibody to alpha-smooth muscle actin (dilution 1:50; DAKO, Glostrup, Denmark) at 37°C for 1 hour.
Evaluation of Immunoreactivity
The staining results were evaluated under a light microscope and assessed semiquantitatively by 2 investigators (E.L. and Y.S.) independently. Immunostaining results for i-NOS and e-NOS were evaluated separately in alveolar macrophages, type II pneumocytes, bronchial epithelial cells, and granulomas, when present. The immunostaining was evaluated quantitatively by interpreting the percentage of positively staining cells. The intensity of the staining reactions was graded as negative, weak, moderate, or intense. The intensities obtained by the 2 investigators showed good agreement, with kappa values between 0.67 and 0.98. 26
Reverse Transcription-Polymerase Chain Reaction for i-NOS, e-NOS, and XAO
The BAL fluid was centrifuged (400g, 15 minutes), and the cells were collected, frozen, and stored at -70°C. Expression of i-NOS, e-NOS, and XAO in the BAL fluid from patients with usual interstitial pneumonia, sarcoidosis, or extrinsic allergic alveolitis and from healthy control subjects was studied by using reverse transcription-polymerase chain reaction (RT-PCR). The oligonucleotide primers were selected according to the complementary DNA (cDNA) sequence data published earlier. [27] [28] [29] Total cellular RNA was extracted from the cells using a kit for RNA isolation (RNEasy, Qiagen, Hilden, Germany). One microgram of RNA was treated with DNAse I (Pharmacia, Biotech, Milwaukee, WI) at 37°C for 10 minutes and at 75°C for 10 minutes to eliminate possible DNA contamination of the samples and reverse transcribed with 100 U of Moloney murine leukemia virus reverse transcriptase (Gibco BRL, Paisley, Scotland) and the respective antisense primer (i-NOS 5'-GGTGCTGCTTGTTAGGAGGTCAAGTAA-AGGGC-3', 5 pmol; e-NOS 5'-AGCTCGCTCTCCCTAA-GCTGGTAGG-3', 7 pmol; XAO 5'-AAGCTTCTGGTT-GAAGTGTGTC-3', 5 pmol) at 42°C for 45 minutes in a 20-µL reaction mixture containing 1 U RNAse inhibitor (5 Prime → 3 Prime, Boulder, CO). The cDNA was PCR-amplified in a thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) using 1 U of DNA polymerase (Dynazyme, Finnzymes, Espoo, Finland) and the respective sense primer (i-NOS 5'-TGCCTGGCAAGCC-CAAGGTCTATGTTCAGGAC-3', 5 pmol; e-NOS 5'-GCAT-CACCTATGACACCCTCAGCG-3', 7 pmol; XAO 5'-TTCCTGGCCAGATACAAGGTTG-3', 5 pmol) in a 100-µL reaction volume containing a 1.5-mmol/L concentration of magnesium chloride.
The thermal profile involved 35, 43, or 40 cycles (i-NOS, e-NOS, and XAO, respectively) of denaturation at 94°C for 50 seconds, primer annealing at 64°C (i-NOS, e-NOS) or 60°C (XAO) for 50 seconds, and extension at 72°C for 1 minute 30 seconds (i-NOS, XAO) or 50 seconds (e-NOS). PCR products were electrophoresed in an ethidium bromide-stained 2% agarose gel (Seakem, Rockland, ME) and visualized under UV light. The amplification products of the i-NOS, e-NOS, and XAO RT-PCRs were 500, 277, and 354 base pairs (bp) in length, respectively. Negative controls were established in each experiment by substituting the RNA sample with water and by leaving the reverse transcriptase enzyme out of the RT-reaction for each of the samples.
Results
Immunohistochemical Results for i-NOS and e-NOS in Normal Lung Tissue Samples
Normal peripheral lung tissue samples showed weak i-NOS expression only in alveolar macrophages ❚Table 1❚ and ❚Image 1A❚. No staining was observed in bronchiolar epithelium or type II pneumocytes. e-NOS showed positivity in alveolar macrophages and bronchial epithelium, and to a lesser degree in endothelial cells of muscular and nonmuscular arterioles ❚Table 2❚ and ❚Image 1B❚. The staining pattern of i-NOS and e-NOS was intracytoplasmic and granular. Vascular endothelium showed positive immunoreactivity for e-NOS in all cases studied.
Immunohistochemical Results for i-NOS and e-NOS in Usual Interstitial and Desquamative Interstitial Pneumonias
The lung biopsy specimens from 9 patients with usual interstitial pneumonia showed stronger immunoreactivity for i-NOS in alveolar macrophages, regenerating type II pneumocytes, and bronchial epithelium than in normal lung tissue samples ❚Table 3❚ and ❚Image 1C❚. Positivity for i-NOS also could be detected in the metaplastic bronchiolar epithelium of the diseased lung. Given that cells of the fibrotic loci, fibroblasts, and especially myofibroblasts, have an important role in the progression of fibrosis, 30 the expression of i-NOS was assessed in these lesions of usual interstitial pneumonia, also evaluating alpha-smooth muscle actin expression in these same areas. Myofibroblasts showed weak positivity for i-NOS, but the immunoreactivity was negative in end-stage fibrotic lesions, ie, areas that showed only fibrotic tissue but no fibroblastic foci. However, a cell population of acute fibroblastic foci showed prominent i-NOS expression, so apparently cells other than myofibroblasts are responsible for i-NOS immunoreactivity in the fibroblastic foci. The lung biopsy specimens from patients with desquamative interstitial pneumonia showed i-NOS immunoreactivity in alveolar macrophages, type II pneumocytes, and bronchial epithelial cells ❚Image 1D❚. In usual interstitial pneumonia, e-NOS positivity could be detected in the ciliated columnar epithelial cells, which showed intracellular positivity for e-NOS at the apical compartment. Both usual interstitial pneumonia and desquamative interstitial pneumonia showed very similar e-NOS positivity in alveolar macrophages, bronchial epithelial cells, endothelial cells, and regenerating type II pneumocytes ❚Table 4❚, ❚Image 1E❚, and ❚Image 1F❚. In contrast with i-NOS, myofibroblasts showed distinct e-NOS immunoreactivity.
Immunohistochemical Results for i-NOS and e-NOS in Granulomatous Diseases
The biopsy specimens from 14 patients with pulmonary sarcoidosis and 5 lung biopsy specimens and 3 transbronchial
G H ❚Image 1❚ (cont) E, Expression of e-NOS in usual interstitial pneumonia (original magnification ×170). F, Negative control (original magnification ×80). G, Expression of i-NOS in the granulomas of sarcoidosis (original magnification ×80). H, A part of the epithelioid cells stained intensively for e-NOS in the granulomas of sarcoidosis (original magnification ×170).
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biopsy specimens from patients with extrinsic allergic alveolitis showed positivity for i-NOS in granulomas of the lung; the immunoreactivity was localized especially to the giant cells ❚Table 5❚ and ❚Image 1G❚. Alveolar macro-phages and regenerating type II pneumocytes showed intensive and bronchial epithelium weak to moderate immunoreactivity for i-NOS in most cases. Granulomas stained positively for e-NOS as well, but the localization within the granulomas was different, not the giant cells but a part of the epithelioid cells stained intensively for e-NOS ❚Image 1H❚. As in the control lung tissue sample, positive e-NOS immunoreactivity could be detected in alveolar macrophages and bronchiolar epithelium ❚Table 6❚. 
Immunohistochemical Analysis for XAO in Healthy and Diseased Lung Tissue Samples
Our study with the aminoethyl carbazole substrate method confirmed recent findings with diaminobenzidine 25 that XAO is negative in healthy human lung tissue samples and that it is expressed highly in human small intestine samples (data not shown). The immunoreactivity of XAO also was negative in all pulmonary diseases with the exception of occasional weak positivity in bronchial epithelium of the biopsy specimens from patients with sarcoidosis, usual interstitial pneumonia, or desquamative interstitial pneumonia ❚Image 2❚. The immunoreactivity of XAO in alveolar macrophages was mainly negative, although very faint immunoreactivity could be detected in the biopsy specimens of diseased lung.
RT-PCR for i-NOS, e-NOS, and XAO
To further study the synthesis of i-NOS, e-NOS, and especially XAO in the cells of BAL fluid and alveolar macrophages, the messenger RNA expression of these enzymes was assessed by PCR in usual interstitial pneumonia, sarcoidosis, extrinsic allergic alveolitis, and healthy control samples. As expected, RT-PCR indicated positivity of i-NOS and e-NOS, but also XAO in all cases studied ❚Image 3❚.
Discussion
Our findings indicate that i-NOS has an important role in the inflammatory phase of human interstitial lung diseases. Since superoxide and NO are known to react with each other and lead to the formation of toxic nitrogen metabolites in the cells, simultaneous production of superoxide and NO probably have a crucial role in the progression of these diseases as well. We emphasize that, in contrast with i-NOS, strong e-NOS immunoreactivity also was observed in alveolar macrophages and bronchial epithelium of the control lung samples, and XAO was mainly negative in all lung diseases studied. Given that NO upregulates the synthesis of transforming growth factor (TGF)-beta, 32 and growth factors are known to down-regulate NO synthase, 30 NO theoretically may contribute to disease progression without exogenous production of superoxide. In agreement with this, intense immunoreactivity of i-NOS could be detected in alveolar macrophages and in the active fibroblast foci of usual interstitial pneumonia, whereas the expression of i-NOS was not detectable in old fibrotic lesions of these diseases. This is the first study on i-NOS in histopathologically classified interstitial pneumonias. The expression of i-NOS in human lung has been documented in numerous previous studies. Normal human airway epithelium expresses low levels of i-NOS, 6 ,11 whereas i-NOS is up-regulated in inflammatory lung diseases such as asthma. 11 i-NOS also has been shown to be induced in alveolar macrophages, neutrophils, and alveolar epithelium, as has e-NOS in airway epithelium and vascular endothelium in patients with unclassified idiopathic pulmonary fibrosis. 12 Our results are in agreement with those of previous studies showing prominent e-NOS but not i-NOS expression in normal lung tissue samples. These results also are consistent with a previous study showing most prominent i-NOS expression in alveolar macrophages and alveolar epithelium of the fibrotic lung. 12 In addition to earlier data, 12 we assessed the expression of i-NOS in usual interstitial pneumonia and desquamative interstitial pneumonia, and these results suggested prominent i-NOS immunoreactivity at the alveolar level and bronchial epithelium of usual interstitial pneumonia and desquamative interstitial pneumonia, but no immunoreactivity in old fibrotic lesions, indicating the importance of i-NOS in acute phases of chronic interstitial pneumonia.
In the present study, we observed very weak i-NOS expression in the myofibroblasts of the fibroblastic foci of the patients with usual interstitial pneumonia. In vitro studies have showed that NO up-regulates the synthesis of TGF-beta, 32 and TGF-beta decreases the i-NOS expression in rat lung fibroblasts. 30 In agreement with this, fibroblasts have been shown to express i-NOS in an acute experimental model of posttransplant obliterative airway disease. 33 It also has been described that TGF-beta is associated strongly with human pulmonary fibrosis. 34 We are not aware of any studies on i-NOS in human lung fibroblasts. The only available study on i-NOS in pulmonary fibrosis did not show any i-NOS immunoreactivity in the fibrotic lung, 12 a result that is consistent with our findings. It therefore is possible that inflammatory cytokines and oxidants stimulate i-NOS in the acute phase of interstitial pneumonia; NO may then further stimulate the synthesis of growth factors in human lung, which finally leads to the down-regulation of i-NOS during the progression of the disease. Interestingly, myofibroblasts of the acute myofibroblastic foci were positive for e-NOS, which indicates that despite the down-regulation of i-NOS, there is still NO production in the fibroblastic foci by e-NOS. The epithelial cells lining the fibroblastic foci were positive for i-NOS, which also might contribute to NO production. These findings suggest further the importance of epithelial cells in NO generation and the contribution of epithelium in i-NOS-related fibrogenesis.
Sarcoidosis and extrinsic allergic alveolitis are granulomatous disorders that seldom lead to pulmonary fibrosis. The most important inflammatory cells in sarcoidosis and extrinsic allergic alveolitis are lymphocytes. Differences in the cell profile and cytokines in usual interstitial pneumonia and granulomatous diseases may partly explain the rarity of fibrosis, and these differences also may contribute to the expression of i-NOS in these disorders. Our results with i-NOS are consistent with the findings in a study on i-NOS expression in pulmonary sarcoidosis 35 and with experimental granulomatous reactions. [13] [14] [15] However, the localization of e-NOS has not been described previously in these disorders. In addition to i-NOS, epithelioid cells of the granulomas show prominent e-NOS immunoreactivity.
Only one relatively recent immunohistochemical study investigated XAO in healthy human lung samples, and no expression of XAO could be detected in any cell type of human lung. 23 Previous studies have not found XAO reactivity or activity in the homogenates of healthy human lung. [21] [22] [23] 25 Experimental studies have shown that XAO can be released into the circulation on reoxygenation, but this finding has not been confirmed in humans. 21 We could not detect XAO in any parenchymal lung disease by immunohistochemical analysis, with the exception of a very faint immunoreactivity observed occasionally in 2) , extrinsic allergic alveolitis (lanes 3 and 4), and usual interstitial pneumonia (lanes 5 and 6). Lane 7, Cells harvested from the BAL fluid of a healthy person; lane 8, U937 cell line, known to express e-NOS 31 ; lane 9, U937 cell line without reverse transcriptase enzyme in the RT-reaction; lane 10, negative control, the RNA sample being substituted with water; lane 11, 100-base-pair (bp) molecular size marker. In positive cases, an amplification product of 277 bp, 500 bp, and 354 bp is formed in e-NOS, i-NOS, and XAO RT-PCRs, respectively. bronchial epithelium. Alveolar macrophages were positive for XAO by RT-PCR, but the immunoreactivity of XAO protein also in these cells was negative or very faint. This might be related to posttranscriptional regulatory mechanisms. It must be noted, however, that immunohistochemical analysis is not sensitive enough for detecting minor amounts of enzyme protein in the samples. These results suggest that XAO may not have a substantial role in the progression of human interstitial lung disorders.
i-NOS may have an important role in the pathogenesis and progression of interstitial lung diseases. Up-regulation of i-NOS was associated mainly with the inflammatory but not with the fibrotic phase of these diseases, in agreement with the induction of this enzyme by inflammatory cytokines and stimulation of the synthesis of fibrogenetic growth factors by NO. This is the first study on XAO in human lung diseases showing that this enzyme has probably no role in the progression of these diseases.
